Gain Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · Three Months Ended June 30, · Six Months Ended June 30, · | |||||||||||||
| · 2024 · 2023 · 2024 · 2023 | |||||||||||||
| Revenues: · · · · · | |||||||||||||
| Collaboration revenues | | $— | | $— | | $— | | $55,180 | | ||||
| Other income | | — | | — | | — | | — | | ||||
| Total revenues | | $— | | $— | | $— | | $55,180 | | ||||
| | | | | | | | | | | | | | |
| Operating expenses: | | | | | | | | ||||||
| Research and development | | (4,437,631) | | (3,987,943) | | | (6,944,537) | | | (6,779,148) | | ||
| General and administrative | | (3,745,193) | | (3,743,171) | | | (5,615,987) | | | (6,236,930) | | ||
| Total operating expenses | | (8,182,824) | | (7,731,114) | | | (12,560,524) | | | (13,016,078) | | ||
| | | | | | | | | | | | | | |
| Loss from operations | | $(8,182,824) | | $(7,731,114) | | $(12,560,524) | | $(12,960,898) | | ||||
| | | | | | | | | | | | | | |
| Other income/(expense): | | | | | | ||||||||
| Interest income, net | | 84,531 | | 129,929 | | 199,834 | | 281,964 | | ||||
| Foreign exchange gain/(loss), net | | (43,576) | | (60,195) | | 224,501 | | (103,037) | | ||||
| Loss before income tax | | $(8,141,869) | | $(7,661,380) | | $(12,136,189) | | $(12,781,971) | | ||||
| | | | | | | | | | | | | | |
| Income tax | | (1,209) | | (26,589) | | (21,083) | | (43,317) | | ||||
| | | | | | | | | | | | | | |
| Net loss | | $(8,143,078) | | $(7,687,969) | | $(12,157,272) | | $(12,825,288) | | ||||
| | | | | | | | | | | | | | |
| Net loss per shares: | | | | | | ||||||||
| Net loss per share attributable to common stockholders - basic and diluted | | $(0.42) | | $(0.62) | | $(0.65) | | $(1.05) | | ||||
| Weighted average common shares - basic and diluted | | 19,215,582 | | 12,387,089 | | 18,600,683 | | 12,157,969 | | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.